Related Experiment Videos

Cromolyn DSG effects in hyperkinetic and psychotic children with allergies

Annals of Allergy
|June 1, 1979
PubMed

Insights

Cromolyn shows promise as a safe and effective treatment for hyperkinetic and psychotic children. Further research is recommended to confirm its benefits in child psychiatry and understand its effects on hyperactivity.

Area of Science:

  • Child Psychiatry
  • Neurodevelopmental Disorders
  • Pharmacology

Background:

  • Hyperkinetic and psychotic disorders in children present complex treatment challenges.
  • Current therapeutic options for these conditions have limitations.
  • Understanding the biochemical underpinnings of pediatric hyperkinesis is crucial.

Purpose of the Study:

  • To evaluate the preliminary efficacy and tolerability of cromolyn in children with hyperkinetic and psychotic symptoms.
  • To assess the safety profile of cromolyn in a pediatric population.
  • To identify potential indications for cromolyn in child psychiatric practice.

Main Methods:

  • An open-label trial was conducted.
  • Participants included children diagnosed with hyperkinetic and psychotic conditions.
  • The study assessed the usability, safety, and tolerability of the medication.

Main Results:

  • Preliminary findings indicate that cromolyn is useful, safe, and well-tolerated in the studied pediatric population.
  • The medication demonstrated a positive initial response in children with hyperkinetic and psychotic symptoms.
  • No significant adverse events were reported, suggesting good tolerability.

Conclusions:

  • Cromolyn appears to be a potentially beneficial and safe therapeutic option for hyperkinetic and psychotic children.
  • Controlled studies are warranted to definitively establish the efficacy and specific indications of cromolyn in child psychiatry.
  • Positive outcomes could offer insights into the biochemical mechanisms underlying hyperkinesis.

Related Concept Videos